Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review

Lancet

Volumn 370, Issue 9584, 2007, Pages 319-328

  Moore, Theresa HM ^a   Zammit, Stanley ^a,b   Lingford Hughes, Anne ^a   Barnes, Thomas RE ^c   Jones, Peter B ^d   Burke, Margaret ^a   Lewis, Glyn ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS;

ANXIETY DISORDER; ARTICLE; BIOSIS; CINAHL; CONFIDENCE INTERVAL; DATA EXTRACTION; DEPRESSION; DOSE RESPONSE; EMBASE; HUMAN; LONGITUDINAL STUDY; MEDLINE; MENTAL HEALTH; MOOD DISORDER; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PSYCHOSIS; PSYCINFO; QUALITY CONTROL; RISK; SUICIDE; SYSTEMATIC REVIEW; UNCERTAINTY;

EID: 34447619511     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)61162-3     Document Type: Article

References (69)

1. NSDUH. Results from the 2004 National Survey on Drug Use and Health: national findings (2005), Substance Abuse and Mental Health Services Administration, Rockville
2. EMCDDA. The state of the drugs problem in Europe: annual report 2005 (2005), European Monitoring Centre for Drugs and Drug Addiction
3. WHO. Cannabis: a health perspective and research agenda (1997), World Health Organization
4. Webb E., Ashton C., Kelly P., and Kamali F. Alcohol and drug use in UK university students. Lancet 348 (1996) 922-925
5. Fergusson D., and Horwood L. Cannabis use and dependence in a New Zealand birth cohort. N Z Med J 113 (2000) 156-158
6. Schneider M., and Koch M. Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology 28 (2003) 1760-1769
7. D'Souza D., Perry E., MacDougall L., et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29 (2004) 1558-1572
8. Isbell H., Gorodetzsky C., Jasinski D., Claussen U., von Spulak F., and Korte F. Effects of (--)delta-9-trans-tetrahydrocannabinol in man. Psychopharmacologia 11 (1967) 184-188
9. Melges F., Tinklenberg J., Deardorff C., Davies N., Anderson R., and Owen C. Temporal disorganization and delusional-like ideation. Processes induced by hashish and alcohol. Arch Gen Psychiatry 30 (1974) 855-861
10. Renault P., Schuster C., Freedman D., Sikic B., and de Mello D. Repeat administration of marihuana smoke to humans. Arch Gen Psychiatry 31 (1974) 95-102
11. Keeler M. Marihuana induced hallucinations. Dis Nerv Syst 29 (1968) 314-315
12. Tart C. Marijuana intoxication common experiences. Nature 226 (1970) 701-704
13. Thomas H. A community survey of adverse effects of cannabis use. Drug Alcohol Depend 42 (1996) 201-207
14. RCP. Cannabis and cannabis-based medicines (2005), Royal College of Physicians, London
15. Arseneault L., Cannon M., Witton J., and Murray R. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 184 (2004) 110-117
16. Degenhardt L., Hall W., and Lynskey M. Exploring the association between cannabis use and depression. Addiction 98 (2003) 1493-1504
17. Henquet C., Murray R., Linszen D., and van Os J. The environment and schizophrenia: the role of cannabis use. Schizophr Bull 31 (2005) 608-612
18. Macleod J., Oakes R., Copello A., et al. Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. Lancet 363 (2004) 1579-1588
19. Semple D., McIntosh A., and Lawrie S. Cannabis as a risk factor for psychosis: systematic review. J Psychopharmacol 19 (2005) 187-194
20. DerSimonian R., and Laird N. Meta-analysis in clinical trials. Control Clin Trials 7 (1986) 177-188
21. Higgins J., and Thompson S. Quantifying heterogeneity in a meta-analysis. Stat Med 21 (2002) 1539-1558
22. Egger M., Davey Smith G., Schneider M., and Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997) 629-634
23. Stroup D., Berlin J., Morton S., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 283 (2000) 2008-2012
24. Tien A., and Anthony J. Epidemiological analysis of alcohol and drug use as risk factors for psychotic experiences. J Nerv Ment Dis 178 (1990) 473-480
25. Henquet C., Krabbendam L., Spauwen J., et al. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 330 (2005) 11
26. van Os J., Bak M., Hanssen M., Bijl R., de Graaf R., and Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol 156 (2002) 319-327
27. Wiles N., Zammit S., Bebbington P., Singleton N., Meltzer H., and Lewis G. Self-reported psychotic symptoms in the general population: results from the longitudinal study of the British national psychiatric morbidity survey. Br J Psychiatry 188 (2006) 519-526
28. Andreasson S., Allebeck P., Engstrom A., and Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 2 (1987) 1483-1486
29. Zammit S., Allebeck P., Andreasson S., Lundberg I., and Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 325 (2002) 1199
30. Zammit S. An investigation into the use of cannabis and tobacco as risk factors for schizophrenia. PhD thesis (2004), Cardiff University
31. Arseneault L., Cannon M., Poulton R., Murray R., Caspi A., and Moffitt T. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 325 (2002) 1212-1213
32. Caspi A., Moffitt T., Cannon M., et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 57 (2005) 1117-1127
33. Fergusson D., Horwood L., and Swain-Campbell N. Cannabis dependence and psychotic symptoms in young people. Psychol Med 33 (2003) 15-21
34. Fergusson D., Horwood L., and Ridder E. Tests of causal linkages between cannabis use and psychotic symptoms. Addiction 100 (2005) 354-366
35. Fergusson D., Lynskey M., and Horwood L. The short-term consequences of early onset cannabis use. J Abnorm Child Psychol 24 (1996) 499-512
36. Fergusson D., and Horwood L. Early onset cannabis use and psychosocial adjustment in young adults. Addiction 92 (1997) 279-296
37. Fergusson D., Horwood L., and Swain-Campbell N. Cannabis use and psychosocial adjustment in adolescence and young adulthood. Addiction 97 (2002) 1123-1135
38. McGee R., Williams S., Poulton R., and Moffitt T. A longitudinal study of cannabis use and mental health from adolescence to early adulthood. Addiction 95 (2000) 491-503
39. Block J., and Gjerde P. Personality antecedents of depressive tendencies in 18-year-olds: a prospective study. J Pers Soc Psychol 60 (1991) 726-738
40. Bovasso G. Cannabis abuse as a risk factor for depressive symptoms. Am J Psychiatry 158 (2001) 2033-2037
41. Crum R., and Anthony J. Cocaine use and other suspected risk factors for obsessive-compulsive disorder: a prospective study with data from the epidemiologic catchment area surveys. Drug Alcohol Depend 31 (1993) 281-295
42. Brook J., Cohen P., and Brook D. Longitudinal study of co-occurring psychiatric disorders and substance use. J Am Acad Child Adolesc Psychiatry 37 (1998) 322-330
43. Brook D., Brook J., Zhang C., Cohen P., and Whiteman M. Drug use and the risk of major depressive disorder, alcohol dependence, and substance use disorders. Arch Gen Psychiatry 59 (2002) 1039-1044
44. Beard J., Dietrich U., Brooks L., Brooks R., Heathcote K., and Kelly B. Incidence and outcomes of mental disorders in a regional population: the Northern Rivers Mental Health Study. Aust N Z J Psychiatry 40 (2006) 674-682
45. Brook J., Rosen Z., and Brook D. The effect of early marijuana use on later anxiety and depressive symptoms. NYS Psychologist (January 2001) 35-40 (New York)
46. Patton G., Coffey C., Carlin J., Degenhardt L., Lynskey M., and Hall W. Cannabis use and mental health in young people: cohort study. BMJ 325 (2002) 1195-1198
47. Borowsky I., Ireland M., and Resnick M. Adolescent suicide attempts: risks and protectors. Pediatrics 107 (2001) 485-493
48. Wade T., and Pevalin D. Adolescent delinquency and health. Can J Criminol Crim Just 47 (2005) 619-654
49. Wilcox H. The development of suicide ideation and attempt: an epidemiologic study of first graders followed into young adulthood. PhD thesis (2003), John Hopkins University
50. Juon H., and Ensminger M. Childhood, adolescent, and young adult predictors of suicidal behaviors: a prospective study of African Americans. J Child Psychol Psychiatry 38 (1997) 553-563
51. Newcomb M., Scheier L., and Bentler P. Effects of adolescent drug use on adult mental health: a prospective study of a community sample. Exp Clin Psychopharmacol 1 (1993) 215-241
52. Newcomb M., Vargas-Carmona J., and Galaif E. Drug problems and psychological distress among a community sample of adults: predictors, consequences, or confound?. J Commun Psychol 27 (1999) 405-429
53. Windle M., and Wiesner M. Trajectories of marijuana use from adolescence to young adulthood: predictors and outcomes. Dev Psychopathol 16 (2004) 1007-1027
54. Paton S., Kessler R., and Kandel D. Depressive mood and adolescent illicit drug use: a longitudinal analysis. J Genet Psychol 131 (1977) 267-289
55. Kandel D., and Davies M. Adult sequelae of adolescent depressive symptoms. Arch Gen Psychiatry 43 (1986) 255-262
56. Henquet C., Rosa A., Krabbendam L., et al. An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology 31 (2006) 2748-2757
57. Smith N. A review of the published literature into cannabis withdrawal symptoms in human users. Addiction 97 (2002) 621-632
58. Allott K., Chanen A., and Yuen H. Attrition bias in longitudinal research involving adolescent psychiatric outpatients. J Nerv Ment Dis 194 (2006) 958-961
59. Fischer E., Dornelas E., and Goethe J. Characteristics of people lost to attrition in psychiatric follow-up studies. J Nerv Ment Dis 189 (2001) 49-55
60. Degenhardt L., Hall W., and Lynskey M. Testing hypotheses about the relationship between cannabis use and psychosis. Drug Alcohol Depend 71 (2003) 37-48
61. Hickman M., Vickerman P., Macleod J., Kirkbride J., and Jones P. Cannabis and schizophrenia: model projections of the impact of the rise in cannabis use on historical and future trends in schizophrenia in England and Wales. Addiction 102 (2007) 597-606
62. Smith G., and Ebrahim S. Data dredging, bias, or confounding. BMJ 325 (2002) 1437-1438
63. Wald D., Wald N., Morris J., and Law M. Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence. BMJ 333 (2006) 1114-1117
64. Chen J., Marmur R., Pulles A., Paredes W., and Gardner E. Ventral tegmental microinjection of delta 9-tetrahydrocannabinol enhances ventral tegmental somatodendritic dopamine levels but not forebrain dopamine levels: evidence for local neural action by marijuana's psychoactive ingredient. Brain Res 621 (1993) 65-70
65. Pistis M., Ferraro L., Pira L., et al. Delta(9)-tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: an in vivo microdialysis study. Brain Res 948 (2002) 155-158
66. Rodriguez de Fonseca F., Del Arco I., Bermudez-Silva F., Bilbao A., Cippitelli A., and Navarro M. The endocannabinoid system: physiology and pharmacology. Alcohol Alcohol 40 (2005) 2-14
67. Heresco-Levy U. Chapter XVII-3: Amino acid transmitter systems. In: D'haenen H., den Boer J., and Willner P. (Eds). Biological psychiatry (2002), Wiley, Chichester 587-600
68. Egger M., Schneider M., and Davey Smith G. Spurious precision? Meta-analysis of observational studies. BMJ 316 (1998) 140-144
69. O'Shea M., McGregor I., and Mallet P. Repeated cannabinoid exposure during perinatal, adolescent or early adult ages produces similar longlasting deficits in object recognition and reduced social interaction in rats. J Psychopharmacol 20 (2006) 611-621